Introduction
Tissue acidosis has been observed as a regular phenomenon following inflammation, ischaemia, arthritis, cancer, hematomas, and exercise [1] [2] [3] . Local tissue pH has been found to drop to 5.4 in purulent exudates, 4.7 in fracture-related hematomas, 5.0-4.0 in bone cancer, and 6.0 in patients with occlusive arterial diseases in the leg [3] . Considering the painful nature of all the conditions above, the high proton concentration might be a significant contributor to the associated pain [1, 4] . Previous studies also suggest that a strong reciprocal pain potentiating interaction exists between acidic pH and several inflammatory mediators and neurotransmitters, with low pH playing the dominant role [5] [6] [7] . The acid-sensing ion channels (ASICs) play an important role in the activation of nociceptors by low pH and thus may serve as potential targets for analgesic drug developing [3, 4, 6, [8] [9] [10] .
Human and animal studies have shown that acid can induce both transient and sustained pain [3, 4, 11] . An acid-induced pain model in rats has been proven to be safe and without significant tissue damage by histological biopsy compared with other inflammation or tumour-induced pain models in rodents [11] . Using acid to produce pain in human skin and muscle has also proven safe [12] [13] [14] . Primary mechanical hyperalgesia was reported to be observed following the acid stimulation. In spite of the different methods adopted, the intensity of the acid-induced pain is pH-dependent [3, 7, 13, 14] . A previous study including intramuscular acidic stimulation reported that women experienced higher referred pain and exhibited a stronger correlation between local and referred pain than men [13] .
Animal studies have reported that repeated intramuscular acidic stimulations induced spinal hyperexcitability with contralaterally spreading hyperalgesia [8, 11, 15, 16] . Local anaesthetics applied to the muscle previously injected with acidic saline could not inhibit the acid-induced contralateral spreading of hyperalgesia [11] indicating a central origin of the phenomenon. However, spreading of pain has not been found after repeated acid injection into the masseter muscle in neither human [12] nor animal studies [17] . Since the results from human research within this field are limited, further studies should be conducted to elucidate the possible central mechanism of acid-induced muscle pain.
The aims of this human study were to investigate: (1) whether acid-induced muscle pain and (2) pressure hyperalgesia were pH dependent; (3) if spreading sensitization could be evoked by repeated versus single injection of acid stimulation; and (4) if there were gender differences in any of the parameters.
Methods

Subjects
Twenty healthy subjects (7 women, 24.3 ± 3.1 years) participated in a three-session study with a single infusion in each session. Further, 12 of the 20 subjects (4 women, 24.1 ± 2.8 years) participated in sessions with repeated infusions. None of the subjects had a history of pain or injuries or medical conditions that could interfere with normal somatosensory functioning. Women in the menstrual period were avoided. The study was approved by the local ethics committee (N 2011-0081) and conducted in accordance with the Declaration of Helsinki. All subjects gave written informed consent.
Experimental protocol
The subjects participated in three sessions; each with a single infusion of buffered saline with one of three different pH levels (pH 5.0, 6.0 and 7.4). The infusions were conducted in random order and with a one-week interval between sessions. Further, 12 subjects received repeated infusions of either pH 5.0 or pH 7.4 solution with a one-day interval between infusions. In each session, neutral phosphate buffered saline (10 ml) was infused into the brachioradialis muscle over 20 min using a computer-controlled infusion pump.
Cold pain threshold (CPT), heat pain threshold (HPT), mechanical pain sensitivity (MPS), and pressure pain threshold (PPT) were assessed before, during, after, one hour after, and one day after the infusion. The pain intensity was rated by means of an electronic visual analogue scale (VAS). A McGill Pain Questionnaire and a pain map were completed after each infusion.
Acidic infusions and pain assessment
The pH adjusted phosphate buffered saline (10 mL, Hospital Pharmacy of Aalborg University Hospital, Aalborg, Denmark) was randomly infused into the left brachioradialis muscle (2 cm from the superior border of cubital fossa) in a double-blinded manner with respect to the pH level. The infusion site was cleaned with alcohol and dried prior to the needle insertion. The needle (27 G, 19 mm, BD Microlance 3, Becton Dickinson, Ireland) was inserted into middle part of the brachioradialis muscle with a depth of 15 mm. The inserted needle was fixed to the skin using surgical tape and sterile cotton. A tube (200 cm, 1.5 ml, G30303M, Care Fusion, Switzerland) was connected to the needle from the syringe. The sterile buffers were infused at a constant rate of 30 ml/h for 20 min using a computer-controlled infusion pump (Asena CC MK-III, Alaris medical systems, USA). The needle and tube were removed immediately after completion of the infusion.
The subjects rated the induced pain intensity on an electronic VAS on which "0 cm" indicated "no pain" and "10 cm" represented "most pain imaginable". The VAS signal was sampled every 2 s from the beginning of the infusion until the pain intensity had returned to zero. The maximal pain (VAS peak) and the area under the curve (VAS area) were calculated. After the infusion, the subjects were asked to draw the pain areas on an arm drawing describe the quality of the pain on the McGill Pain Questionnaire (MPQ).
Assessment sites
Two sites in the infusion side and two sites in the contralateral side were assessed (Fig. 1) . CPT, HPT MPT, and PPT were assessed 1 cm from the infusion site (T2). All sensory assessments were also conducted at the infusion site (T1) at the same time points except during infusion. Further, the assessments were performed on the contralateral arm at the corresponding sites as controls (C2 and C1).
Cutaneous thermal pain sensitivity
Cold pain threshold (CPT) and heat pain threshold (HPT) were measured (TSA 2001 II (CHEPS, Medoc, Israel) at T1 and C1 sites. The contact area of the thermode was 9 cm 2 . The baseline temperature was 32 • C (centre of neutral range). The method of limits was used by applying ramp stimuli at a velocity of 1 • C/s. The cut-off temperatures were 0 • C and 55 • C. The volunteers were asked to press a button when the respective thermal sensations were perceived. The mean threshold temperature of three consecutive measurements was calculated.
Cutaneous mechanical pain sensitivity
The cutaneous sensitivity was assessed using weight-calibrated pins (128 mN, custom made Aalborg University) at all assessment sites. The subjects rated the cutaneous mechanical pain sensitivity (MPS) on a 0-5-10 Numeric Rating Scale (NRS) on which "0" represented "no sensation", "5" represented "pain threshold", and "10" presented "worst pain imaginable". The mean of the three measurements was used in the statistical analysis.
Pressure pain sensitivity
A hand-held pressure algometer (Somedic AB, Sweden) was used to assess the PPTs. The pressure was applied to all assessment sites at a constant rate of 30 kPa/s through a 1 cm 2 probe. The subjects were instructed to push a button immediately when they felt the pressure turning into pain. The PPTs were measured twice at each site. The interval between the two PPT trials was at least 40 s and the mean of the two measurements was used in the statistical analysis.
Statistics
The normal distribution was checked for all data. The necessary logarithmic transformation was performed [18] . QST data were then analysed using a 3-way repeated measure analysis of variance (ANOVA) with gender as between-subject factor and testing site (T1, T2, C1, C2), pH levels (pH 5.0, 6.0, 7.4) and time (baseline, during, after, one hour after, and one day after) as within-subject factors. The VAS scores and pain areas of the different pH levels and of the single and repeated infusions were analysed by 2-way (pH level and gender) repeated measure of ANOVA. A Bonferroni test was employed for post hoc comparisons in case of significant ANOVAs. All statistical calculations were performed using the Statistical Package for Social Sciences version 20 (SPSS, IBM). The significance level was set at P < 0.05. The data are presented as mean and standard error of the mean (SEM).
Results
Acidic-evoked pain
The VAS profiles of the three infusions with different pH levels are shown in Fig. 2A . Significant differences were detected in VAS peak (ANOVA: P < 0.023, Fig. 2B ) and VAS area (ANOVA: P < 0.012, Fig. 2C ). The infusion of the pH 5.0 solution caused higher VAS scores (Peak 4.65) than the pH 6.0 solution (Peak 3.37) (P = 0.015) and the 7.4 solution (1.68) (P = 0.001). In addition, the pH 7.4 solution The pain areas following the three different solutions are illustrated in Fig. 3 . Infusion of the pH 5.0 solution evoked a larger area than infusion of pH 6.0 (P = 0.036) and 7.4 (P = 0.004), whereas the pH 7.4 solution evoked the smallest area compared with pH 6.0 and pH 5.0 solution (P < 0.021).
No gender differences were detected in VAS peak, VAS area, or drawing areas (P > 0.092).
Cutaneous thermal and mechanical pain sensitivity
The ANOVA of the CPT, HPT, or MPS among the different solutions at any of the tested sites were not significant (ANOVA: P > 0.073). Likewise, no significant change was detected before, during, immediately after, one hour after, and one day after the infusion (ANOVA: P > 0.103,) or between gender (ANOVA: P > 0.087, data not presented).
Pressure pain sensitivity
The ANOVA demonstrated that the PPTs were different over time (ANOVA: P < 0.017) but not between solutions pH levels (P > 0.092). Compared with baseline, relative PPTs decreased immediately after, 1 h after, and 1 day after the infusion at T1 (P < 0.017) and during infusion at the T2 site (P < 0.030) (Fig. 4AB) . No significant difference was detected in the contralateral sites (ANOVA: P > 0.105; Fig. 4C and D) and no gender difference was found (ANOVA: P > 0.087).
Repeated infusions
Eight out of 12 subjects received repeated infusion of pH 5.0 solution, and 4 of them received repeated infusion of pH 7.4 solution No significant difference in VAS scores was detected between the two repeated sessions for neither pH 5.0 nor pH 7.4 (P > 0.195) (Fig. 5A) . No difference was detected in CPT, HPT, MPS or PPT between the two repeated sessions for either pH 5.0 or pH 7.4 (ANOVA: P > 0.106, data not presented). Normalized PPT values after the 1st and 2nd infusion of pH 5.0 is shown in Fig. 5B. 
Discussion
The intensity of the acid-induced muscle pain was pH dependent whereas the deep tissue pressure hyperalgesia was not pH dependent. Repeated acid stimulation did not induce more pain or prolonged pressure hyperalgesia as compared with a single injection. No gender differences were found.
Acid-induced muscle pain
In the present study, the single infusions of the pH solution into the human forearm muscle produced significantly higher pain intensities than the neutral buffer (pH 7.4) and the pH 6.0 buffer infusions, which is consistent with previous studies on acidic muscle pain models [13, 19] . The study is the first to use infusion of buffered saline with different pH levels into the same group of human muscles. The results provide clear evidence that the acidevoked pain was pH dependent. The thin myelinated Group III and unmyelinated Group IV nerve fibres in muscle are responsible for transmitting muscular nociceptive information and their endings are sensitive to inflammatory mediators including low pH stimulation [20, 21] . The decrease in tissue pH following muscle ischaemia is believed to activate ASICs in muscle nociceptors, thus contributing to e.g. ischaemic muscle pain [8, 19, 22, 23] . Clinically it is known that local anaesthetics with pH levels as low as 5 occasionally produce transient pain upon injection [24, 25] . Thus acidic infusion could be used as a muscle pain model in both animal and human studies.
Factors affecting the pain evoked by acid infusions
Factors such as infusion volume and muscle size could affect acid-evoked pain intensity. In the present study, a total of 10 ml of buffered acid saline was infused into the brachioradialis muscle at a rate of 30 ml/h. The average peak pain intensity of the evoked pain was 4.65 cm for the pH 5.0, 3.37 cm for the pH 6.0, and 1.68 pH 7.4 solution (Fig. 2) . In previous animal and human studies, different volumes were used to induce pain. In studies examining male rats, acidic saline was injected in volumes of 20 L into the rat masseter [26] and rat gastrocnemius muscle [8] which successfully evoked pain and hyperalgesia. However, in human studies with injection of 0.5 ml unbuffered acid saline, approximately 3% of the total volume of the human masseter muscle which was comparable to the relative injection volume used in the rats, no significant pain was induced when compared with neutral saline injections [12] . Infusion of five times the volume (2.5 mL) of unbuffered acidic saline into the masseter muscle of human subjects induced pain levels similar to the results of single injection (0.5 ml) in previous study [27] . Thus, the results of the previous human studies did not provide evidence that the injection/infusion volume had a major impact on the acid-induced pain intensity. It seems other factors, such as infusion rate, and using buffered saline may play more important role in the acid-evoked pain intensity. However, the injection or infusion volume should be considered according to the muscle volume when using an acid infusion as pain model.
The infusion rate may play an important role in the acid-evoked pain. A previous study on acid-induced human skin pain indicated that raising the infusion rate leads to increasing pain by lowering the local pH more effectively and by increasing the tissue volume in which the proton concentration exceeds the threshold to excite nociceptors [28] . Infusion of isotonic pH 5.2 phosphate buffer into the flexor carpi radialis muscle produced pain correlated with the flow rate of the infusion [19] . In a recent human study, acid saline (pH 3.3) was infused into the masseter muscle with a slow infusion rate of 15 ml/h. The infusion evoked only mild pain and no mechanical allodynia or increased release of algesic substances assessed by microdialysis were detected [27] . In our previous study, acid saline (pH 5.2) was infused into the anterior tibialis muscle and the pain level was higher and PPTs were lower following an infusion rate of 40 mL/h compared to the infusion rate of 20 ml/h [13] . In the present study, the infusion rate of 30 mL/h was selected since the expected pain intensity was evoked by both pH 5.0 and pH 6.0 buffered saline during the pilot experiments when the different infusion rates of 10 ml, 20 ml, 30 ml, and 40 ml were tested.
In addition, using buffered saline instead of unbuffered saline might be the necessary to evoke pain. Previous human studies have suggested that acid-induced muscle pain may be more effectively produced by infusion of low pH (∼5) phosphate buffers [13, 28] than by injections of unbuffered acidic saline [12, 27] . Recent human studies did not evoke the expected pain by means of unbuffered acid saline with pH 3.3 [12, 27] . This difference is possibly due to the ability of the muscle tissue to rapidly buffer pH changes after injections of acidic solutions. Compared with a buffered saline solution, an unbuffered saline solution could physiologically regain pH level more quickly because of the buffering capacity of the muscle tissue. Since ACIC3 channels generate sustained currents as long as the pH is acidic [29] , the longer the pH in the muscle remains acidic and the longer the ASIC3 channels will be activated.
Mechanical hyperalgesia
In the present healthy human study, PPT values at the infusion site (T1) and around the infused site (T2) were significantly decreased during the acidic infusion compared with baseline. However, no mechanical hyperalgesia was observed in the contralateral side indicating that the acidic infusion caused local sensitisation without central mechanisms being involved. Further, no significant difference was detected in the three different pH solutions indicating that the local mechanical hyperalgesia was not pH-dependent but most likely a volume effect. Similar mechanical hyperalgesia was observed in the experimental muscle pain model conducted by injecting acidic buffer into the anterior tibialis muscle [13] . In contrast, in a recent human study acid-infusion into the masseter muscle did not evoke mechanical hyperalgesia in either the local or contralateral side [27] . It seems that only localised pain and short period local hyperalgesia were observed after infusion of acidic buffer in human studies.
Gender differences
No sex-related differences in pain intensity, pain areas, or induced local pressure hyperalgesia were observed among the three different infusions in the present study. A previous study of intramuscular acidic stimulation reported that women experienced higher referred pain and exhibited a stronger correlation between local and referred pain than men [13] . In rats, expression of ASIC 3 receptors is greater in masseter muscle sensory afferent fibres in females compared with males [30] . It is unclear if a similar difference in ASIC channel expression occurs in humans or if the expression of ASIC channels by sensory afferent fibres varies depending on the muscle assessed. The present study only included a relatively small study sample. The non-significant findings may have resulted from inadequate statistical power. Future studies in humans may help to address whether there indeed sex-related differences in acid induced muscle pain.
Effect of repeated acid infusions
In animal studies, repeated intramuscular injections of acidic saline produced a prolonged bilateral mechanical hyperalgesia lasting up to 30 days [11] providing the first insight into the molecular mechanisms underlying the development of chronic muscle hyperalgesia [8] . However, in the present human study, contralateral spreading of pain and hyperalgesia was not observed following repeated infusions of acidic saline. In line, repeated infusion of unbuffered acidic saline into human masseter muscle did not evoke any mechanical hyperalgesia in either the local or the contralateral side [12, 27] . Repeated infusions into the tibialis muscle induced short-lasting (20 min) local hyperalgesia without involving the contralateral side [13] . It is not clear why the repeated acidic infusion in humans did not reproduce any long-lasting and widespread hyperalgesia similar to those in animals. It should be noted that conflicting results were also found in a previous animal study where the mechanical allodynia could not be detected after two repeated injections of acidic saline into the masseter muscle [17] . The modality differences between acidic saline, buffered or unbuffered, flow rate, infusion volume, intervals between repeated infusions, different muscles, trigeminal region vs spinal region, and evoked pain intensity are likely to contribute to the controversial results. Another explanation might be the difference in the total amount of acid stimulation between the animal and human studies as a larger part of the muscle was actually stimulated in the animals; whereas only a small part of the muscle was affected in humans. Again, the relatively smaller sample size may also contribute to the negative result.
Conclusions
Infusions into the brachioradialis muscle induced pain that was pH-dependent and mechanical hyperalgesia that was pH independent. However, repeated intramuscular acidic saline injection model of prolonged hyperalgesia in rodents could not be translated into a human for modelling chronic musculoskeletal pain.
Implications
The acid-induced pain model may reflect the early stage responses to tissue injury of clinical conditions. It was not possible to use this human intramuscular acidic saline infusion model to produce the type of prolonged local and widespread hyperalgesia that has previously been demonstrated to occur in animal models.
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